MLV Maintains Buy On Conatus Pharmaceuticals Following Phase 1 Data In Hepatic Impairment


In a research report released today, MLV analyst Vernon Bernardino maintained a Buy rating on Conatus Pharmaceuticals (NASDAQ:CNAT) with a $16 price target, as the company reported late-breaking results from a phase 1 study with emricasan in patients with hepatic impairment.

Bernardino noted, “We believe the results were robust, better than expected, and support emricasan’s potential to directly affect outcomes in the acute liver disease setting.”

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Vernon Bernardino has a total average return of -24.3% and a 0.0% success rate. Bernardino has a -3.7% average return when recommending CNAT, and is ranked #3329 out of 3365 analysts.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts